Last reviewed · How we verify
Fluimucil® 2% solution
At a glance
| Generic name | Fluimucil® 2% solution |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus (NA)
- Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (PHASE3)
- A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluimucil® 2% solution CI brief — competitive landscape report
- Fluimucil® 2% solution updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI